公开(公告)号：US20230404998A1

公开(公告)日：2023-12-21

申请号：US18298800

申请日：2023-04-11

Applicant: ASCENTAGE PHARMA (SUZHOU) CO., LTD. ,  ASCENTAGE PHARMA GROUP CORP LIMITED ,  GUANGZHOU HEALTHQUEST PHARMA CO., LTD.

Inventor： Yifan ZHAI ,  Dajun YANG ,  Guangfeng WANG ,  Miaozhen QIU ,  Fan LUO

IPC: A61K31/496 ,  A61K31/4439 ,  A61K39/395 ,  A61P35/02

CPC classification number: A61K31/496 ,  A61K31/4439 ,  A61K39/3955 ,  A61P35/02 ,  A61K2039/505

Abstract: The present invention relates to one or more combination treatments of cancer patients with a compound of formula (I),






and an allosteric inhibitor or an immune checkpoint molecule, wherein R1 and R2 are as described herein.

公开(公告)号：US20230399400A1

公开(公告)日：2023-12-14

申请号：US18249054

申请日：2021-10-14

Applicant: I-MAB BIOPHARMA CO., LTD.

Inventor： Zhengyi Wang ,  Wei Cao ,  Bingshi Guo ,  Cong Xu

IPC: C07K16/28 ,  A61P35/02 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/02 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/24 ,  C07K2317/76 ,  A61K2039/545

Abstract: Provided herein are CD47 antibodies and immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination. Also provided are as well as pharmaceutical compositions containing such antibodies or antibody fragments, as well as methods of treatment using such antibodies, e.g., as single agents or in combination with other therapeutic agent (s).

公开(公告)号：US20230391866A1

公开(公告)日：2023-12-07

申请号：US18014229

申请日：2021-07-06

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Siddhartha MUKHERJEE ,  Abdullah Mahmood ALI ,  Alan BURKE ,  Florence BOROT

IPC: C07K16/28 ,  C07K14/74 ,  A61P35/02

CPC classification number: C07K16/2803 ,  C07K16/2809 ,  C07K14/70539 ,  A61P35/02 ,  C07K16/283 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/732 ,  A61K2039/505

Abstract: Disclosed herein are engineered heterodimer or heterotrimer proteins which use a non-naturally occurring polypeptide domain comprising 1-5 alpha helices connected by amino acid linkers and an IgG2 hinge domain either alone or in conjunction with an IgG2 Fc domain. The heterodimer and heterodimer proteins can further comprise an antigen-binding fragment that binds a lineage-specific cell-surface antigen, a polypeptide that binds to a molecule expressed on an immune cell (e.g., natural killer cell) and/or a polypeptide that binds to a molecule expressed on another type of immune cell (e.g., T cells). Also disclosed herein are nucleic acids encoding the proteins, vectors comprising the nucleic acids, compositions, and methods of treatment.

公开(公告)号：US20230391817A1

公开(公告)日：2023-12-07

申请号：US18034317

申请日：2021-10-28

Applicant: DENDROGENIX

Inventor： Stéphane SILVENTE ,  Quentin MARLIER ,  Arnaud RIVES ,  Nicolas CARON ,  Dario MOSCA ,  Hélène MICHAUX

IPC: C07J43/00 ,  A61K45/06 ,  A61P35/02

CPC classification number: C07J43/003 ,  A61P35/02 ,  A61K45/06

Abstract: The invention relates to a novel compound of general formula (I):




and/or a pharmaceutically acceptable salt of such a compound, to a pharmaceutical composition comprising at least said compound, for its use as a medicament for shrinking a mammalian cancerous tumor.

公开(公告)号：US20230390278A1

公开(公告)日：2023-12-07

申请号：US18031765

申请日：2021-10-12

Applicant: VESTLANDETS INNOVASJONSSELSKAP AS

Inventor： Bjørn Tore GJERTSEN ,  Vibeke ANDRESEN ,  Calum LEITSCH

IPC: A61K31/473 ,  A61K31/19 ,  A61P35/02 ,  A61K9/20

CPC classification number: A61K31/473 ,  A61K31/19 ,  A61P35/02 ,  A61K9/20

Abstract: The present invention relates to synergistic combinations of quinacrine and valproic acid for the treatment of cancer, preferably acute myeloid leukaemia (AML); and methods of treating cancer using such synergistic combinations.

公开(公告)号：US20230365557A1

公开(公告)日：2023-11-16

申请号：US18223860

申请日：2023-07-19

Applicant: 1ST Biotherapeutics, Inc.

Inventor： Jinhwa LEE ,  Suyeon JO ,  Keonseung LIM ,  A Yeong PARK ,  Jae Eun KIM ,  Misoon KIM ,  Seung Mook LIM

IPC: C07D471/04 ,  A61P25/28 ,  A61P25/16 ,  C07D519/00 ,  A61P35/02 ,  A61K31/437 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61P25/28 ,  A61P25/16 ,  C07D519/00 ,  A61P35/02 ,  A61K31/437 ,  A61K45/06

Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.

公开(公告)号：US20230364246A1

公开(公告)日：2023-11-16

申请号：US18080140

申请日：2022-12-13

Applicant: THE BURLINGTON HC RESEARCH GROUP, INC.

Inventor： Dale M. WALKER ,  Vernon E. WALKER ,  Tsvetelina I. LAZAROVA ,  Steven W. RIESINGER

IPC: A61K47/60 ,  A61K31/145 ,  A61P31/14 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K47/60 ,  A61K31/145 ,  A61P31/14 ,  A61P35/00 ,  A61P35/02

Abstract: In one aspect, the present application relates to an aminothiol-conjugate of formula (I):




wherein








R1, R2, R3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).

公开(公告)号：US20230355767A1

公开(公告)日：2023-11-09

申请号：US18304883

申请日：2023-04-21

Applicant: ONEHEALTHCOMPANY, INC.

Inventor： Benjamin Lewis ,  Christina Kelly Lopes ,  Lindsay Lambert ,  Garrett Harvey ,  Thaddeus A. Allen ,  Aubrey Miller ,  Lucas Rodrigues ,  Madison Luker ,  Gerald Post

IPC: A61K41/00 ,  A61P35/02

CPC classification number: A61K41/00 ,  A61P35/02 ,  A61P35/00

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

公开(公告)号：US11802160B2

公开(公告)日：2023-10-31

申请号：US16782440

申请日：2020-02-05

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C12N15/85

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20230341375A1

公开(公告)日：2023-10-26

申请号：US18216405

申请日：2023-06-29

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Joshua Hansen ,  Courtney G. Havens ,  Antonia Lopez-Girona, SR. ,  Gang Lu ,  Daniel W. Pierce ,  Lilly L. Wong

IPC: G01N33/50 ,  G01N33/68 ,  G01N33/574 ,  A61K31/496 ,  A61P35/02

CPC classification number: G01N33/5011 ,  G01N33/6869 ,  G01N33/57484 ,  A61K31/496 ,  G01N33/6866 ,  A61P35/02 ,  G01N2800/52 ,  A61K45/06

Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.